Daf2 Inhibitors
Daf2 inhibitors are a class of chemical compounds that specifically target the DAF-2 protein, an insulin/insulin-like growth factor 1 (IGF-1) receptor homolog found in the nematode Caenorhabditis elegans. These inhibitors are instrumental in research settings for modulating the insulin/IGF-1 signaling (IIS) pathway, which is pivotal in controlling growth, development, metabolism, and lifespan in these organisms. Chemically, Daf2 inhibitors may consist of small molecules that bind to the extracellular domain of the DAF-2 receptor, preventing ligand interaction, or they might interfere with the receptor's intracellular kinase activity, thus inhibiting downstream signaling. The inhibition of DAF-2 activity by these compounds allows researchers to dissect the molecular mechanisms of the IIS pathway and understand how it influences various physiological processes.
The target protein, DAF-2, is a transmembrane tyrosine kinase receptor that, upon activation by its ligands, initiates a phosphorylation cascade involving downstream effectors such as AGE-1 (a phosphoinositide 3-kinase), AKT-1, and AKT-2 kinases. This signaling ultimately affects the activity of DAF-16, a forkhead box O (FOXO) transcription factor homolog. When DAF-2 is inhibited, DAF-16 translocates to the nucleus and regulates the expression of genes involved in stress resistance, metabolism, and longevity. Daf2 inhibitors, therefore, are valuable tools for studying the regulation of gene expression mediated by DAF-16 and for exploring how alterations in the IIS pathway can lead to changes in an organism's physiology. By modulating DAF-2 activity, these inhibitors help elucidate the complex interactions between signaling pathways that govern development and aging in C. elegans.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin inhibits phosphoinositide 3-kinase (PI3K), disrupting the PI3K/AKT pathway. This impacts insulin signaling and may indirectly inhibit Daf2 by altering downstream events in the insulin signaling cascade, affecting cellular processes associated with insulin sensitivity and longevity regulation. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor affecting the PI3K/AKT pathway. By disrupting insulin signaling, it indirectly influences Daf2, potentially altering cellular processes associated with insulin sensitivity and aging. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, disrupting the mTOR signaling pathway. Its indirect impact on Daf2 involves modulation of nutrient sensing and downstream cellular processes associated with aging and longevity regulation. | ||||||
2-Deoxy-D-glucose | 154-17-6 | sc-202010 sc-202010A | 1 g 5 g | $70.00 $215.00 | 26 | |
2-Deoxy-D-glucose inhibits glycolysis, impacting energy metabolism. Its indirect inhibition of Daf2 involves altering cellular energy homeostasis and downstream processes associated with insulin sensitivity and aging. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 inhibits mTOR, disrupting the mTOR signaling pathway. Its indirect modulation of Daf2 involves interference with nutrient sensing and downstream cellular processes associated with aging and longevity regulation. | ||||||
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
SB216763 inhibits GSK-3, impacting the Wnt signaling pathway. Indirectly, it influences Daf2 by altering Wnt signaling and downstream cellular processes associated with insulin sensitivity and aging. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK1/2, disrupting the MAPK/ERK pathway. Its indirect influence on Daf2 involves modulation of MAPK signaling and downstream cellular processes associated with insulin sensitivity and aging regulation. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, impacting the JNK signaling pathway. Its indirect modulation of Daf2 involves interference with JNK signaling and downstream cellular processes associated with insulin sensitivity and aging regulation. | ||||||
AICAR | 2627-69-2 | sc-200659 sc-200659A sc-200659B | 50 mg 250 mg 1 g | $65.00 $280.00 $400.00 | 48 | |
AICAR activates AMP-activated protein kinase (AMPK), influencing cellular energy homeostasis. Its indirect impact on Daf2 involves AMPK activation, altering downstream processes associated with insulin sensitivity and aging regulation. | ||||||
AG 1024 | 65678-07-1 | sc-205907 | 1 mg | $107.00 | 22 | |
AG1024 inhibits IGF-1 receptor, disrupting the IGF-1 signaling pathway. Its indirect modulation of Daf2 involves interference with IGF-1 signaling and downstream cellular processes associated with insulin sensitivity and aging regulation. | ||||||